Want to see ORKA full AI Analyst Report?
Top Page
Oruka Therapeutics
(NASDAQ:ORKA)
Select Model
Select Model
Rating:60Neutral
Price Target:
$98.00
▲(42.19% Upside)
Action:Reiterated
Date:06/23/26
The score is primarily driven by a strong balance sheet with minimal leverage, but offset by being pre-revenue with expanding losses and heavy cash burn. Technicals are supportive due to strong momentum, though overbought signals raise near-term risk. Positive clinical trial news improves the outlook, while valuation remains constrained by ongoing losses and no dividend.
Positive Factors
Strong balance sheet / low leverage
Extremely low debt and sizable equity provide durable financial flexibility, lowering refinancing and interest risk. This supports multi-year clinical programs, M&A or licensing optionality, and gives management time to de-risk assets before needing dilutive financing.
Negative Factors
Pre-revenue with widening losses
No product revenue and materially increasing losses mean long-term value hinges entirely on clinical success and future commercialization. This raises execution risk and potential dilution if programs delay or need additional financing before revenue generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet / low leverage
Extremely low debt and sizable equity provide durable financial flexibility, lowering refinancing and interest risk. This supports multi-year clinical programs, M&A or licensing optionality, and gives management time to de-risk assets before needing dilutive financing.
Read all positive factors
Oruka Therapeutics (ORKA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.14B
Dividend YieldN/A
Average Volume (3M)1.28M
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue GrowthN/A
EPS Growth54.61%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.39
Shares Outstanding60,312,100
10 Day Avg. Volume1,264,458
30 Day Avg. Volume1,278,814
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.93
Price to Sales (P/S)0.00
P/FCF Ratio-15.64
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-36.72K
Enterprise Value/Ebitda-22.44
Forecast
1Y Price Target
$151.20Price Target Upside119.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.11
Revenue Forecast (FY)N/A
Oruka Therapeutics Business Overview & Revenue Model
Company Description
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunologic...
How the Company Makes Money
null...
Oruka Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -71.00K | -83.00K | -27.00K | -114.00K | -91.00K | -93.00K |
| EBITDA | -116.14M | -105.35M | -82.23M | -9.81M | -19.23M | -9.64M |
| Net Income | -116.25M | -105.43M | -83.72M | -9.93M | -19.32M | -9.74M |
Balance Sheet | ||||||
| Total Assets | 504.48M | 488.62M | 396.02M | 43.09M | 54.92M | 50.43M |
| Cash, Cash Equivalents and Short-Term Investments | 388.83M | 337.04M | 375.65M | 42.45M | 53.36M | 49.07M |
| Total Debt | 1.81M | 1.93M | 968.00K | 383.00K | 483.00K | 450.00K |
| Total Liabilities | 17.76M | 16.69M | 13.80M | 1.41M | 3.88M | 3.91M |
| Stockholders Equity | 486.72M | 471.93M | 382.22M | 41.67M | 51.04M | 46.52M |
Cash Flow | ||||||
| Free Cash Flow | -91.19M | -88.42M | -58.03M | -10.91M | -18.80M | -7.74M |
| Operating Cash Flow | -90.92M | -88.21M | -57.84M | -10.91M | -18.76M | -7.72M |
| Investing Cash Flow | -154.05M | -96.75M | -330.13M | -2.00K | -43.00K | -19.00K |
| Financing Cash Flow | 210.91M | 170.31M | 449.54M | 0.00 | 23.09M | 48.45M |
Oruka Therapeutics Technical Analysis
Positive
68.92
Price Trends
68.72
Positive
56.28
Positive
41.96
Positive
Market Momentum
7.67
Negative
60.85
Neutral
69.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORKA, the sentiment is Positive. The current price of 68.92 is below the 20-day moving average (MA) of 76.49, above the 50-day MA of 68.72, and above the 200-day MA of 41.96, indicating a bullish trend. The MACD of 7.67 indicates Negative momentum. The RSI at 60.85 is Neutral, neither overbought nor oversold. The STOCH value of 69.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORKA.
Oruka Therapeutics Risk Analysis
Oruka Therapeutics disclosed 1 risk factors in its most recent earnings report. Oruka Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oruka Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $5.14B | -35.65 | -25.99% | ― | ― | 54.61% | |
60 Neutral | $1.88B | -74.61 | 442.91% | ― | 107.73% | 82.33% | |
56 Neutral | $1.53B | ― | -35.89% | ― | ― | -63.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $408.80M | -5.34 | -39.75% | ― | -100.00% | -2.72% | |
48 Neutral | $395.43M | -1.80 | -486.41% | ― | 395.85% | 21.44% | |
48 Neutral | $1.10B | -6.26 | -45.95% | ― | ― | -3.83% |
* Healthcare Sector Average
ORKA
Oruka Therapeutics
85.21
72.61
576.27%
VSTM
Verastem
4.50
-0.30
-6.25%
ANAB
AnaptysBio
63.42
47.59
300.63%
CMPX
Compass Therapeutics
2.27
-0.37
-14.02%
OLMA
Olema Pharmaceuticals
12.64
8.19
184.04%
BCAX
Bicara Therapeutics Inc.
29.00
19.99
221.86%
Oruka Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Oruka Therapeutics Shareholders Back Governance and Executive Pay
Positive
Jun 4, 2026
At its June 2, 2026 annual meeting, Oruka Therapeutics stockholders elected two Class II directors, Lawrence Klein and Chris Martin, to serve on the board until the 2029 annual meeting, reinforcing continuity in the company’s governance stru...
Business Operations and StrategyRegulatory Filings and Compliance
Oruka Therapeutics Expands IL-23 License, Adds Dosing Limits
Neutral
Jun 1, 2026
On May 29, 2026, Oruka Therapeutics, Inc. amended its IL-23 License Agreement with Paragon Therapeutics, Inc. to expand the licensed field for its IL-23 program, including ORKA-001, to cover all therapeutic, prophylactic, palliative and diagnostic...
Financial DisclosuresPrivate Placements and Financing
Oruka Therapeutics Completes Public Equity Offering Under Shelf
Neutral
Apr 30, 2026
On April 28, 2026, Oruka Therapeutics entered into an underwriting agreement with a syndicate of investment banks to offer 9,660,000 shares of common stock at $72.50 per share, including a 30‑day option for underwriters to buy up to 1,449,00...
Business Operations and StrategyProduct-Related Announcements
Oruka Therapeutics Reports Strong Phase 2 Psoriasis Results
Positive
Apr 27, 2026
On April 27, 2026, Oruka Therapeutics reported positive interim results from its Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis, with 63.5% of treated patients achieving complete skin clearance (PASI 100 and identical...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.